Last reviewed · How we verify
ATX101
ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | ATX101 |
|---|---|
| Sponsor | Aurobac Therapeutics SAS |
| Drug class | sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting Nav1.5, ATX101 is thought to reduce the excitability of cardiac myocytes, thereby preventing the initiation and maintenance of atrial fibrillation. This mechanism of action is specific to the treatment of atrial fibrillation for stroke prevention.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma (PHASE1)
- Phase 1 Single Ascending Dose Study With ATX101 (PHASE1)
- Study Assessing Pain Relief After Replacement of the Knee (PHASE2)
- Study Assessing Pain Relief After Replacement of the Knee (PHASE2)
- Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat (NA)
- A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy (PHASE1, PHASE2)
- ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (PHASE2)
- Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATX101 CI brief — competitive landscape report
- ATX101 updates RSS · CI watch RSS
- Aurobac Therapeutics SAS portfolio CI